Miyazaki Prefectural Miyazaki Hospital
Welcome,         Profile    Billing    Logout  
 28 Trials 
40 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Isambert, Nicolas
MULTISARC, NCT03784014: Molecular Profiling of Advanced Soft-tissue Sarcomas

Active, not recruiting
3
603
Europe
Nilotinib, TASIGNA, Ceritinib, ZYKADIA, Capmatinib, Lapatinib, TYVERB, Trametinib, MEKINIST, Trametinib and Dabrafenib, MEKINIST and TAFINLAR, Olaparib and Durvalumab, LYNPARZA, MEDI4736, Palbociclib, IBRANCE, PD-0332991, Glasdegib, PF-04449913, TAS-120, Next Generation sequencing exome, RNA Seq, NGS, High throughput sequencing
Institut National de la Santé Et de la Recherche Médicale, France, Commissariat A L'energie Atomique, Institut Bergonié, Plateforme labellisée Inca - Institut Bergonié, Bordeaux, Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris, EUCLID Clinical Trial Platform
Soft Tissue Sarcoma
12/23
10/25
CIRSARC, NCT03805022: Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas

Recruiting
3
351
Europe
Doxorubicin, Ifosfamide or dacarbazine, At the discretion of the investigator
Institut Bergonié, Novartis, Chugai Pharma France
Non-metastatic Soft-tissue Sarcoma, Resectable
02/25
02/25
RAR-Immune, NCT04741438: Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype

Recruiting
3
96
Europe
Nivolumab and IPILIMUMAB, Pazopanib Oral Tablet [Votrient]
Centre Leon Berard
Sarcoma
02/25
08/25
CHIC-STS01, NCT04307277: Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma

Recruiting
3
600
Europe
Standard of care + chemotherapy, Standard of care
Institut Claudius Regaud
Soft Tissue Sarcoma
03/25
03/25
MOIO, NCT05078047: Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients With Metastatic Cancer in Response After 6 Months of Standard IO

Recruiting
3
646
Europe
Reduced dose intensity of IO
UNICANCER
Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer, Bladder Cancer, Triple Negative Breast Cancer, Merkel Cell Carcinoma, Hepatocellular Carcinoma, Melanoma
03/25
03/25
ELAINEIII, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
400
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
06/25
06/26
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
CAIRE, NCT04705818: Combining Epigenetic And Immune Therapy to Beat Cancer.

Recruiting
2
173
Europe
Durvalumab, Tazemetostat
Institut Bergonié, AstraZeneca, Epizyme, Inc.
Advanced Solid Tumor, Advanced Colorectal Carcinoma, Advanced Soft-tissue Sarcoma, Advanced Pancreatic Adenocarcinoma, Adult Solid Tumor
07/23
01/25
LENVAGIST, NCT04193553: Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure

Completed
2
77
Europe
Lenvatinib, Placebo, Best supportive care
Centre Leon Berard
Gastro Intestinal Stromal Tumour
01/24
04/24
EREMISS, NCT03793361: Phase II Study of Regorafenib as Maintenance Therapy

Active, not recruiting
2
127
Europe
Regorafenib, stivarga, Placebo
Centre Oscar Lambret
Metastatic Soft Tissue Sarcoma
03/24
03/25
CARMEN-LC05, NCT04524689 / 2020-000035-50: Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

Hourglass Apr 2022 - Dec 2022 : Data from CARMEN-LC05 trial in combination with pembrolizumab for PDL1+ advanced NSCLC
Active, not recruiting
2
57
Europe, US, RoW
SAR408701 (Tusamitamab ravtansine), Tusamitamab ravtansine, Pembrolizumab, Keytruda, Cisplatin, Carboplatin, Pemetrexed
Sanofi
Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
03/24
12/24
AGADIR, NCT03915678: Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

Recruiting
2
247
Europe
Association atezolizumab + BDB001 + RT, Association atezolizumab + BDB001+ RT
Institut Bergonié, Roche Pharma AG, National Cancer Institute, France, Eikon Therapeutics
Solid Tumor, Adult, Pancreatic Cancer, Virus-associated Tumors, Non Small Cell Lung Cancer, Melanoma, Bladder Cancer, Triple Negative Breast Cancer
09/24
03/26
TRUST, NCT04874311: Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma

Recruiting
2
80
Europe
Bintrafusp alfa, Doxorubicin
Institut Bergonié, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma
09/24
03/25
TARSARC, NCT04807816: Targeting ATR in Soft-tissue Sarcomas

Recruiting
2
72
Europe
Association of berzosertib with gemcitabine, Experimental, Gemcitabine, Control
Institut Bergonié, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Leiomyosarcoma, Adult
10/24
04/26
ATEZOGIST, NCT05152472: A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments

Recruiting
2
110
Europe
Atezolizumab 1200 mg, Tecentriq®, Imatinib 400 MG, Glivec®
Centre Leon Berard
Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST), Metastatic Gastrointestinal Stromal Tumor
01/25
06/26
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Recruiting
2
252
Europe, Canada, US, RoW
Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
Locally Advanced or Metastatic Urothelial Carcinoma
01/25
01/25
Decrescendo, NCT04675827: De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade

Suspended
2
1065
Europe, RoW
Pertuzumab and tratuzumab fixed dose combination, Adjuvant pertuzumab + trastuzumab FDC SC for 14 cycles, Fixed-dose combination of Perjeta and Herceptin for subcutaneous injection for 14 cycles, Trastuzumab emtansine, Adjuvant T-DM1
Jules Bordet Institute, Breast International Group, Hoffmann-La Roche, International Drug Development Institute, Institut Curie
HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, Node-negative Breast Cancer
06/27
03/29
RIBOLARIS, NCT05296746: Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer

Recruiting
2
1100
Europe
Ribociclib (neoadjuvant), Kisqali, Chemotherapy (adjuvant), Ribociclib (adjuvant)
SOLTI Breast Cancer Research Group, Novartis, UNICANCER
Breast Cancer Stage II
08/28
07/30
METex14, NCT04868877 / 2021-000203-20: A Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Recruiting
1/2
380
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
04/24
04/25
OMNIA-1, NCT05578872: A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma ().

Recruiting
1/2
130
Europe, US
ANV419, Pembrolizumab, Ipilimumab
Anaveon AG
Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor, Metastatic Melanoma
09/24
12/24
ELECTRA, NCT05386108: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer

Recruiting
1/2
106
Europe, US, RoW
Elacestrant, ELA-0121, Abemaciclib, Verzenio
Stemline Therapeutics, Inc.
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
12/25
12/25
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
Apr 2022 - Apr 2022: Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
Checkmark Presentation of Trident -1 data for the treatment of NSCLC in AACR-NCI-EORTC 2021
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
NCT04901806: Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

Terminated
1
29
Europe, US, RoW
PBI-200
Pyramid Biosciences
Solid Tumor, Adult, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor
07/23
07/23
OncoSNIPE, NCT04548960: - Study of Molecular Profiles Associated With the Development of Resistance in Solid Cancer Patients

Recruiting
N/A
600
Europe
cancer patients
Oncodesign SA
CANCER
12/21
03/23
EXOSARC, NCT03800121: Study of Exosomes in Monitoring Patients With Sarcoma

Recruiting
N/A
34
Europe
Blood samples, Localized sarcoma, Metastatic sarcoma
Centre Georges Francois Leclerc
Sarcoma
11/24
11/25
RNASARC, NCT03375437: - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.

Active, not recruiting
N/A
376
Europe
Blood and tumor samples
Centre Leon Berard, Hoffmann-La Roche
Soft Tissue Sarcoma, Advanced Cancer, Metastatic Cancer
02/24
01/25
NEOSarcomics, NCT02789384: CINSARC Signature and Correlation With Hemotherapy Efficacy in Soft-tissue Sarcomas. A Biomarker Study.

Recruiting
N/A
205
Europe
Procedure/Surgery
Institut Bergonié, National Cancer Institute, France, Ministry of Health, France
Soft-tissue Sarcomas
01/25
08/27
REPARP, NCT05378204: Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

Recruiting
N/A
120
Europe
Main study:, Sub-study:
Institut Claudius Regaud, Artios Pharma Ltd
Breast Cancer
01/27
06/27
REGOSTA, NCT04055220 / 2018-004045-16: Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas

Recruiting
N/A
168
Europe
Treatment by Regorafenib, Stivarga, Treatment by Placebo, Standard of care
Centre Leon Berard
Bone Sarcoma, Osteosarcoma, Ewing Sarcoma, Chondrosarcoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma, Angiosarcoma
10/26
10/26
MIRAS, NCT03967834: Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - Project From SARRA (SARcome RAre) Project of the French Sarcoma Group

Recruiting
N/A
400
Europe
Patient with Soft Tissue Sarcoma
Institut Claudius Regaud
Soft Tissue Sarcoma, Clear Cell Sarcoma, Epithelioid Sarcoma, Perivascular Epithelioid Cell Neoplasms, Desmoplastic Small Round Cell Tumor, Malignant Solitary Fibrous Tumors, Alveolar Soft Part Sarcoma, Epithelioid Hemangioendothelioma, Low Grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma
04/31
04/31
BROCARD, Fabien
STRATEGIC-1, NCT01910610 / 2013-001928-19: Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer

Active, not recruiting
3
464
Europe, RoW
FOLFIRI-cetuximab, mFOLFOX6-bevacizumab, OPTIMOX-bevacizumab, irinotecan-based chemo + bevacizumab, Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab), XELOX + bevacizumab
GERCOR - Multidisciplinary Oncology Cooperative Group, Hoffmann-La Roche
Colorectal Cancer Metastatic
07/23
12/24
DOMENICA, NCT05201547 / 2021-002124-21: Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

Recruiting
3
260
Europe, Canada, RoW
Carboplatin-Paclitaxel, Dostarlimab
ARCAGY/ GINECO GROUP, GlaxoSmithKline
Endometrial Cancer
04/26
10/29
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NIRVANA-1, NCT05183984: Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer

Recruiting
2
390
Europe, Japan
Chemotherapy, Bevacizumab-Awwb, Niraparib
ARCAGY/ GINECO GROUP
Ovarian Cancer
02/27
02/30
OPTIPRIME, NCT03584711: FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation

Active, not recruiting
2
118
Europe, RoW
FOLFOX + panitumumab
Federation Francophone de Cancerologie Digestive, Amgen
Metastatic Colorectal Cancer
04/24
12/24
FFCD 1703 POCHI, NCT04262687: Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate

Recruiting
2
55
Europe
Capecitabine, Oxaliplatin, Bevacizumab, Pembrolizumab
Federation Francophone de Cancerologie Digestive
Colorectal Cancer Metastatic, High Immune Infiltrate, Microsatellite Stable
09/24
09/24
Kawano, Jiro
NCT05359081: A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan

Terminated
3
68
Japan
SEP-363856
Sumitomo Pharma Co., Ltd.
Schizophrenia
03/24
03/24
NCT04825860: A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase

Terminated
2/3
83
Japan, RoW
SEP-363856 50 mg, SEP-363856 75 mg, Placebo
Sumitomo Pharma Co., Ltd.
Schizophrenia
10/23
10/23
Greilsamer, Charlotte
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Otomo, Naoki
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32

Download Options